Clinical Trials and Enrollment - Enrollment completed in two pivotal trials of VDPHL01 for male patients, with topline data expected from Study 302 in 1H 2026 and Study 304 in 2H 2026[1] - Over 1,000 male participants enrolled in Studies 302 and 304, representing one of the largest registration-directed programs for pattern hair loss (PHL) to date[4] - Enrollment ongoing in Study 306, the first Phase 2/3 trial of an oral treatment for female pattern hair loss, expected to enroll over 500 female patients[4] Financial Performance - Cash, cash equivalents, and marketable securities totaled $141.9 million as of December 31, 2025, with an upsized IPO raising approximately $294.8 million completed in February 2026[6][7] - Net loss for the fourth quarter of 2025 was $21.8 million, compared to a net loss of $5.7 million for the same period in 2024[11] - Net loss for the year ended December 31, 2025, was $69,995,000, up from a net loss of $26,488,000 in 2024, reflecting a 164% increase[18] - Total other income, net, for the year ended December 31, 2025, was $2,352,000, compared to $290,000 in 2024, reflecting a significant increase[18] Expenses - Research and development (R&D) expenses increased to $62.1 million for the year ended December 31, 2025, compared to $23.3 million for the previous year[11] - General and administrative (G&A) expenses rose to $10.3 million for the year ended December 31, 2025, compared to $3.5 million for the previous year[11] - Research and development expenses increased to $18,192,000 in Q4 2025 from $4,950,000 in Q4 2024, representing a 267% increase[18] - Total operating expenses rose to $23,011,000 in Q4 2025 compared to $5,971,000 in Q4 2024, marking a 285% increase[18] - Loss from operations for the year ended December 31, 2025, was $72,347,000, compared to $26,778,000 in 2024, a 170% increase[18] Assets and Liabilities - Cash, cash equivalents, and marketable securities increased significantly to $141,862,000 in 2025 from $53,084,000 in 2024, a growth of 167%[20] - Total assets grew to $152,619,000 in 2025, up from $55,535,000 in 2024, indicating a 174% increase[20] - Total liabilities increased to $9,156,000 in 2025 from $4,718,000 in 2024, a rise of 94%[20] - Total stockholders' equity and redeemable convertible preferred stock reached $143,463,000 in 2025, compared to $50,817,000 in 2024, representing a 182% increase[20] Leadership Changes - Mark Neumann appointed as Chief Commercial and Strategy Officer, bringing over 30 years of biopharmaceutical experience[7] Product Development - VDPHL01 is an investigational, orally available non-hormonal drug in Phase 3 development for PHL, with a proprietary extended-release formulation designed to improve efficacy and safety[9] - Anticipated milestones for 2026 include two Phase 3 readouts for men and progress towards a planned NDA submission for VDPHL01[2]
VeraDermics(MANE) - 2025 Q4 - Annual Results